Loading
Vebreltinib is a Chinese MET inhibitor approved in 2023 for lung cancers with a MET exon 14 skipping mutation, and the first drug tested in a phase 3 trial for glioblastomas carrying a PTPRZ1-MET fusion.
Beijing Pearl Biotechnology's vebreltinib (PLB1001, also developed as APL-101 by Apollomics) was approved by China's NMPA in November 2023 for locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping. Because it crosses the blood-brain barrier, it was also taken into a randomised phase 3 trial in secondary glioblastoma with PTPRZ1-MET fusions, a rare molecular subgroup identified by Chinese neuro-oncology groups, and a further trial in MET-altered lung cancer is registered.
A selective, brain-penetrant inhibitor of the MET kinase; tumours with MET exon 14 skipping mutations, MET amplification or PTPRZ1-MET fusions depend on that signal. Connects to MET.
1.Vebreltinib slips into a pocket on MET.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2023 | Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Vebreltinib" OR ABSTRACT:"Vebreltinib" OR TITLE:"PLB1001" OR ABSTRACT:"PLB1001" OR TITLE:"Bozitinib" OR ABSTRACT:"Bozitinib" OR TITLE:"APL-101" OR ABSTRACT:"APL-101" OR TITLE:"CBT-101" OR ABSTRACT:"CBT-101") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Vebreltinib, not a curated reading list.
Shares Avistone Biotechnology, Non-small-cell lung cancer and the tag pipeline.
Shares Avistone Biotechnology, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Avistone Biotechnology, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Glioma & glioblastoma and the tag pipeline.